MedTrace Logo

Nicotinic Receptor Augmentation of SSRI Antidepressants

NCT00319319 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2007-04-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether the nicotinic receptor antagonist mecamylamine hydrochloride (Inversine) can augment SSRI-refractory major depression symptoms, quality of life and cigarette smoking outcomes. A total of n=60 SSRI-refractory patients who are on stable doses of an SSRI are being recruited into this 8-week double-blind, randomized, placebo-controlled trial.

Conditions

  • Depressive Disorder

Interventions

DRUG

Mecamylamine hydrochloride (Inversine)

Sponsors & Collaborators

  • Donaghue Medical Research Foundation

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Tony P. George, M.D. · Yale University School of Medicine, Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00319319 on ClinicalTrials.gov